Anandamide Increases the Differentiation of Rat Adipocytes and Causes PPARγ and CB1 Receptor Upregulation

[1]  V. Marzo,et al.  Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.

[2]  L. Marnett,et al.  Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids* , 2008, Journal of Biological Chemistry.

[3]  R. Capasso,et al.  Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High‐fat Diet , 2008, Obesity.

[4]  P. Bernante,et al.  The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. , 2007, The Journal of clinical endocrinology and metabolism.

[5]  A. Karameris,et al.  Monoclonal Antibody 4C5 Immunostains Human Melanomas and Inhibits Melanoma Cell Invasion and Metastasis , 2007, Clinical Cancer Research.

[6]  F. Fezza,et al.  Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. , 2006, Biochimie.

[7]  A. Duranti,et al.  The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. , 2006, Pharmacological research.

[8]  M. Maj,et al.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[9]  J. V. Vanden Heuvel,et al.  Interleukin-2 Suppression by 2-Arachidonyl Glycerol Is Mediated through Peroxisome Proliferator-Activated Receptor γ Independently of Cannabinoid Receptors 1 and 2 , 2006, Molecular Pharmacology.

[10]  Daniele Piomelli,et al.  Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). , 2006, CNS drug reviews.

[11]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[12]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[13]  C. Vorgias,et al.  Anandamide metabolism by Tetrahymena pyriformis in vitro. Characterization and identification of a 66 kDa fatty acid amidohydrolase. , 2005, Biochimie.

[14]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[15]  P. Casellas,et al.  Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. , 2005, European journal of pharmacology.

[16]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[17]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[18]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[19]  R. Hampson,et al.  Cannabinoid physiology and pharmacology: 30 years of progress , 2004, Neuropharmacology.

[20]  N. Kaminski,et al.  A Cyclooxygenase Metabolite of Anandamide Causes Inhibition of Interleukin-2 Secretion in Murine Splenocytes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  D. Piomelli,et al.  Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPAR-α)* , 2004, Journal of Biological Chemistry.

[22]  T. Willson,et al.  Polyunsaturated Fatty Acids Including Docosahexaenoic and Arachidonic Acid Bind to the Retinoid X Receptor α Ligand-binding Domain* , 2004, Molecular & Cellular Proteomics.

[23]  R. Wiesner,et al.  Simple flow cytometric method used to assess lipid accumulation in fat cells Published, JLR Papers in Press, March 1, 2004. DOI 10.1194/jlr.D300028-JLR200 , 2004, Journal of Lipid Research.

[24]  C. Hillard,et al.  Cellular accumulation of anandamide: consensus and controversy , 2003, British journal of pharmacology.

[25]  M. Breschi,et al.  CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  T. Warner,et al.  PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator‐activated receptor‐γ antagonist , 2003 .

[27]  C. Newton,et al.  The cannabinoid system and immune modulation , 2003, Journal of leukocyte biology.

[28]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[29]  H. Mersmann,et al.  Effects of isomers of conjugated linoleic acid on porcine adipocyte growth and differentiation. , 2003, The Journal of nutritional biochemistry.

[30]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[31]  L. Petrocellis,et al.  Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response , 2003, Cellular and Molecular Life Sciences CMLS.

[32]  J. Morrow,et al.  Metabolism of the Endocannabinoids, 2-Arachidonylglycerol and Anandamide, into Prostaglandin, Thromboxane, and Prostacyclin Glycerol Esters and Ethanolamides* , 2002, The Journal of Biological Chemistry.

[33]  D. Dobson,et al.  Altered expression of C/EBP family members results in decreased adipogenesis with aging. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[34]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[35]  M. Elphick,et al.  The neurobiology and evolution of cannabinoid signalling. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[36]  D. Deutsch,et al.  The fatty acid amide hydrolase (FAAH). , 2000, Prostaglandins, leukotrienes, and essential fatty acids.

[37]  C. Fowler,et al.  Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase , 2000, British journal of pharmacology.

[38]  E. Berry,et al.  Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. , 2000, European journal of pharmacology.

[39]  H. Sul,et al.  Understanding adipocyte differentiation. , 1998, Physiological reviews.

[40]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[41]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[42]  M. Rodbell.  METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS. , 1964, The Journal of biological chemistry.

[43]  I. Matias,et al.  Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. , 2008, Biochimica et biophysica acta.

[44]  V. Di Marzo.  Targeting the endocannabinoid system: to enhance or reduce? , 2008 .

[45]  F. Fezza,et al.  Endocannabinoids in adipocytes during differentiation and their role in glucose uptake , 2006, Cellular and Molecular Life Sciences.

[46]  A. A. Spector,et al.  Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. , 2005, Microvascular research.

[47]  S. Gaetani,et al.  Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.

[48]  Millard H. Lambert,et al.  PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE , 2001 .